Celanese Corporation (CE) Stock Price & How to Invest

Celanese Corporation makes chemicals in two very different businesses. Its Acetyl Chain segment produces acetic acid, vinyl acetate monomer, acetate tow and related derivatives, largely commodity molecules sold on price and cost position, and it generated about ~$2.4B of net sales in the first half of 2026. Engineered Materials, the larger half at roughly ~$2.8B of first-half sales, sells specialty polymers, nylon, elastomers and compounds into automotive, medical, electronics and industrial applications where formulations are specified into a customer's part. Around ~11,400 employees run the plant network, which spans North America, Europe and Asia, with a large equity-affiliate presence in China.

Investors are really underwriting a capital structure. Celanese borrowed roughly ~$11B to buy DuPont's Mobility and Materials business in 2022, then walked straight into a multi-year downturn in automotive builds and European industrial demand, so total debt sits near ~$12.0B against about ~$1.4B of cash and only ~$4.6B of book equity. Goodwill write-downs in Engineered Materials, which now total ~$2.7B of accumulated impairment, drove the trailing twelve-month net loss of roughly ~$1.2B even though the first half of 2026 was profitable at ~$177M. Management cut the quarterly dividend by about 95% starting in early 2025, paused buybacks, sold the Micromax business for ~$493M, and amended financial ratio maintenance covenants on its U.S. credit facilities in both 2025 and on July 31, 2026. Compliance held as of June 30, 2026, and the auditor has raised no going-concern doubt, but the equity trades at about half of trailing sales because the outcome sits on a narrower ledge than a chemical company's revenue line implies.

Leverage dominates the risk list. Total debt of roughly ~$12.0B against about ~$4.6B of book equity leaves a debt-to-equity ratio near ~2.7 and an enterprise value of roughly ~$16.3B against a ~$4.8B market cap, so a modest change in enterprise value swings the equity hard in either direction. Celanese amended financial ratio maintenance covenants in its U.S. credit facilities during 2025 and again on July 31, 2026, and while it was in compliance as of June 30, 2026 and expects to remain so, its own filing notes that results materially below expectation could require seeking a further amendment or waiver. On the legal side, follow-on damages claims arising from the company's July 2020 settlement of a European Commission ethylene-purchasing competition investigation remain live: ~14 claims have been filed since 2023 by parties including Shell, Repsol entities, BASF, Dow, ExxonMobil, BP, MOL Group and Braskem in the District Court of Amsterdam and the German courts of Munich and Dortmund, and on July 30, 2026 the Amsterdam court dismissed the Shell and Repsol claims in their entirety as not plausible, a ruling subject to appeal. Celanese states it cannot estimate the potential impact of the remaining matters. Several plaintiff law firms announced investigations of potential securities claims after the November 2024 earnings and guidance disappointment, though no filed securities class action appears in the company's Legal Proceedings disclosure, and the auditors have raised no going-concern doubt.

16 analysts publish price targets on CE, averaging $63.62 against a $44.46 price as of August 2026, or +43.1%. The published targets run from $45.00 to $86.00, a moderate spread, and the ratings split 10 buy, 6 hold, 0 sell. Over the last six months there have been 3 raises and 8 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Celanese Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Deleveraging through cash and asset sales. Every capital-allocation lever Celanese has pulled since late 2024 points the same direction: a ~95% dividend cut, a paused repurchase program, reduced capital spending at roughly ~$128M in the first half of 2026, and the ~$493M Micromax sale to Element Solutions that closed in February. The most optimistic published target, $86.00, assumes this works close to its best case.

The case against. Leverage dominates the risk list. The most pessimistic target, $45.00, is roughly what CE is worth if this bites instead.

Read the full bull and bear case on CE, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Celanese Corporation's investor relations page or your broker.

• Revenue (TTM): ~$9.7B
• Net income (TTM): ~-$1.2B, driven by goodwill and asset impairments
• Market cap: ~$4.8B at roughly ~$44 per share
• Net debt: ~$10.6B (total debt ~$12.0B less cash ~$1.4B)
• Debt to equity: ~2.7x against ~$4.6B of total equity
• Enterprise value / sales: ~1.7x, versus price to sales of ~0.5x

Two very different valuations sit on the same company. Equity holders pay roughly half of trailing sales, which looks cheap until the ~$10.6B of net debt is added and the whole enterprise prices at about ~1.7x sales, a fairly ordinary multiple for a chemical producer in a soft cycle. Free cash flow of roughly ~$708M over the trailing twelve months is what services the debt, and first-half operating cash of ~$285M came in below the prior year on a large working-capital build in receivables.

Other names that sit close to CE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Celanese is a real industrial franchise whose equity value now turns less on chemical demand than on whether cash generation and asset sales can bring roughly ~$10.6B of net debt down before the credit structure forces the issue.

Whether CE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CE a buy or a sell?, and where the stock could go from here in the CE stock forecast.

For income investors, whether CE pays a dividend and how the payout looks is covered in does CE pay a dividend? And to weigh CE against a peer, read the full side-by-side comparisons: CE vs LYB and CE vs EMN.